Clinical Trial of LEVI-04-21-02

This is a Multiple Arm, Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled, Phase 2a study of LEVI-04 intravenous infusion for the treatment of pain due to osteoarthritis of the knee. The purpose of the trial is to evaluate the efficacy, safety, and tolerability of five monthly infusions of LEVI-04 as compared to placebo in participants with radiographic and symptomatic knee osteoarthritis. Up to 624 participants will be enrolled and randomized to one of four Treatment Arms at the ratio 1:1:1:1.

 

Nordic Bioscience is the lead CRO for the LEVI-04-21-02 trial for more information about Nordic https://www.nbcd.com

For information about the LEVI-04-21-02 Phase II clinical trial please click here https://clinicaltrials.gov/ct2/show/NCT05618782

For information about the LEVI-04 Phase I clinical trial please click here https://clinicaltrials.gov/ct2/show/NCT03227796

For general information regarding LEVI-04-21-02 please contact info@levicept.com